FDA Critical Path Initiatives: Opportunities for Generic Drug Development

@article{Lionberger2008FDACP,
  title={FDA Critical Path Initiatives: Opportunities for Generic Drug Development},
  author={Robert A. Lionberger},
  journal={The AAPS Journal},
  year={2008},
  volume={10},
  pages={103-109}
}
FDA’s critical path initiative documents have focused on the challenges involved in the development of new drugs. Some of the focus areas identified apply equally to the production of generic drugs. However, there are scientific challenges unique to the development of generic drugs as well. In May 2007, FDA released a document “Critical Path Opportunities for Generic Drugs” that identified some of the specific challenges in the development of generic drugs. The key steps in generic product… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 48 references

Clinical relevance of alcohol-induced dose dumping

  • R. Meyer
  • Advisory Committee For Pharmaceutical Science…
  • 2008

Speech before annual generic drug forum

  • S. Gottlieb
  • FDA 2006, Available at: http://www.fda.gov/oc…
  • 2008

Topical bioequivalence update

  • R. Lionberger
  • at: Advisory Committee for Pharmaceutical Science…
  • 2008

et al

  • S. H. Haidar, B. Davit, M. L. Chen
  • Bioequivalence approaches for highly variable…
  • 2007

D

  • D. Korn
  • R. Stanski, eds., Drug Development Science…
  • 2005

Similar Papers

Loading similar papers…